TKPHF:OTO-Takeda Pharmaceutical Co Ltd (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic | OTC Pink

Last Closing

USD 26.616

Change

0.00 (0.00)%

Market Cap

USD 35.88B

Volume

72.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Takeda Pharmaceutical Co Ltd is engaged in the manufacturing, marketing and import and export of pharmaceutical drugs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKKGY Merck KGaA ADR

-0.30 (-0.82%)

USD 79.59B
MKGAF MERCK Kommanditgesellschaft au..

-2.50 (-1.37%)

USD 77.98B
HLNCF Haleon plc

-0.02 (-0.50%)

USD 37.62B
TEVJF Teva Pharmaceutical Industries..

N/A

USD 18.32B
SGIOY Shionogi & Co Ltd ADR

-0.09 (-0.78%)

USD 13.81B
SGIOF Shionogi & Co. Ltd

N/A

USD 13.81B
ESALF Eisai Co. Ltd

N/A

USD 12.59B
ESAIY Eisai Co. Ltd.

-0.12 (-1.10%)

USD 12.54B
IPSEY Ipsen SA ADR

N/A

USD 10.63B
IPSEF Ipsen S.A

N/A

USD 10.63B

ETFs Containing TKPHF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.36% 44% F 39% F
Dividend Return 2.43% 80% B- 60% D-
Total Return -4.92% 46% F 41% F
Trailing 12 Months  
Capital Gain -19.86% 58% F 43% F
Dividend Return 4.21% 69% C- 55% F
Total Return -15.65% 59% D- 45% F
Trailing 5 Years  
Capital Gain -27.58% 80% B- 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.58% 80% B- 47% F
Average Annual (5 Year Horizon)  
Capital Gain -3.95% 52% F 31% F
Dividend Return 71.96% 81% B- 80% B-
Total Return 75.90% 89% A- 97% N/A
Risk Return Profile  
Volatility (Standard Deviation) 125.35% 34% F 29% F
Risk Adjusted Return 57.41% 98% N/A 91% A-
Market Capitalization 35.88B 99% N/A 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.